StockNews.AI
ZLAB
StockNews.AI
160 days

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

1. Zai Lab's TIVDAK BLA accepted for recurrent cervical cancer treatment in China. 2. China sees 150,000 new cervical cancer cases annually, highlighting significant treatment demand.

2m saved
Insight
Article

FAQ

Why Bullish?

The acceptance of the BLA is a positive regulatory milestone for ZLAB, similar to previous approvals, which historically led to price increases.

How important is it?

The BLA acceptance indicates significant progress in ZLAB's pipeline, likely attracting investor interest.

Why Long Term?

The approval can enhance ZLAB's market presence and revenue in the long term, given the high incidence rate of cervical cancer in China.

Related Companies

NVCROGENREGN
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. “In China, cervical cancer is a serious health concern with approximately 150,000 new cases diagnosed annually1,”.

Related News